worx11's Top Recommendations

These recommendations were last updated about an hour ago.

	Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. [My Copy] N Engl J Med, Vol. 353, No. 7. (18 August 2005), pp. 653-662. by S. Windecker, A. Remondino, F. R. Eberli, et al.P. Jüni, L. Räber, P. Wenaweser, M. Togni, M. Billinger, D. Tüller, C. Seiler, M. Roffi, R. Corti, G. Sütsch, W. Maier, T. Lüscher, O. M. Hess, M. Egger, B. Meier posted by 1 person scottd2104
	Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. [My Copy] JAMA, Vol. 299, No. 4. (30 January 2008), pp. 409-416. by A. M. Galløe, L. Thuesen, H. Kelbaek, et al.P. Thayssen, K. Rasmussen, P. R. Hansen, N. Bligaard, K. Saunamäki, A. Junker, J. Aarøe, U. Abildgaard, J. Ravkilde, T. Engstrøm, J. S. Jensen, H. R. Andersen, H. E. Bøtker, S. Galatius, S. D. Kristensen, J. K. Madsen, L. R. Krusell, S. Z. Abildstrøm, G. B. Stephansen, J. F. Lassen, posted by 1 person scottd2104
	Effect of a multifactorial intervention on mortality in type 2 diabetes. [My Copy] The New England journal of medicine, Vol. 358, No. 6. (7 February 2008), pp. 580-591. by Peter Gaede, Henrik Lund-Andersen, Hans-Henrik H. Parving, Oluf Pedersen posted by 4 people booker guhjy scottd2104 omalbam
	Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. [My Copy] J Urol, Vol. 170, No. 1. (July 2003), pp. 145-148. by T. M. Johnson, K. Jones, W. O. Williford, M. H. Kutner, M. M. Issa, H. Lepor posted by 1 person scottd2104
	Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. [My Copy] Am J Geriatr Pharmacother, Vol. 3, No. 2. (June 2005), pp. 103-114. by Y. T. Logan, M. T. Belgeri posted by 1 person scottd2104
	The Effect of Doxazosin, Finasteride and Combination Therapy on Nocturia in Men With Benign Prostatic Hyperplasia [My Copy] The Journal of Urology, Vol. 178, No. 5. (November 2007), pp. 2045-2051. by Johnson, Pamela K. Burrows, John W. Kusek, et al.Leroy M. Nyberg, Lisa J. Tenover, Herbert Lepor, Claus G. Roehrborn posted by 1 person scottd2104
	Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. [My Copy] Clin Biochem, Vol. 36, No. 7. (October 2003), pp. 499-504. by A. D. Sniderman, D. Blank, R. Zakarian, J. Bergeron, J. Frohlich posted by 1 person scottd2104
	When to treat dyslipidaemia of patients with chronic renal failure on haemodialysis? A need to define specific guidelines. [My Copy] Nephrol Dial Transplant, Vol. 11, No. 2. (February 1996), pp. 308-313. by J. Pedro-Botet, M. Senti, J. Rubiés-Prat, A. Pelegrí, R. Romero posted by 1 person scottd2104
	Maximal post-prandial triglyceride increase reflects post-prandial hypertriglyceridaemia and is associated with the insulin resistance syndrome. [My Copy] Diabet Med, Vol. 18, No. 1. (January 2001), pp. 32-39. by B. G. Karamanos, A. C. Thanopoulou, D. P. Roussi-Penesi posted by 1 person scottd2104
	Ethnic differences in postprandial triglyceride response to a fatty meal and lipoprotein lipase in lean and obese African American and Caucasian women. [My Copy] Metabolism, Vol. 51, No. 2. (February 2002), pp. 211-217. by J. F. Bower, Y. Deshaies, M. Pfeifer, R. J. Tanenberg, H. A. Barakat posted by 1 person scottd2104
	A clinical comparison of calculated versus direct measurement of low-density lipoprotein cholesterol level. [My Copy] Pharmacotherapy, Vol. 24, No. 2. (February 2004), pp. 167-172. by C. C. Lindsey, M. R. Graham, T. P. Johnston, C. G. Kiroff, A. Freshley posted by 1 person scottd2104
	Gender difference in postprandial lipemia : importance of visceral adipose tissue accumulation. [My Copy] Arterioscler Thromb Vasc Biol, Vol. 19, No. 10. (October 1999), pp. 2448-2455. by C. Couillard, N. Bergeron, D. Prud'homme, et al.J. Bergeron, A. Tremblay, C. Bouchard, P. Mauriège, J. P. Després posted by 1 person scottd2104
	Randomized Evaluation of Atorvastatin in Patients With Coronary Heart Disease. [My Copy] Circ J, Vol. 71, No. 12. (2007), pp. 1845-1850. by Takashi Yamada, Akihiro Azuma, Susumu Sasaki, Takahisa Sawada, Hiroaki Matsubara, posted by 1 person scottd2104
	Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [My Copy] Circulation, Vol. 106, No. 25. (17 December 2002), pp. 3143-3421. posted by 2 people dcvanpelt scottd2104
	Calculated low density lipoprotein cholesterol levels frequently underestimate directly measured low density lipoprotein cholesterol determinations in patients with serum triglyceride levels < or =4.52 mmol/l: an analysis comparing the LipiDirect magnetic LDL assay with the Friedewald calculation. [My Copy] Clin Chim Acta, Vol. 365, No. 1-2. (March 2006), pp. 236-242. by D. A. Tighe, I. S. Ockene, G. Reed, R. Nicolosi posted by 1 person scottd2104
	Diabetes insipidus: diagnosis and treatment of a complex disease. [My Copy] Cleve Clin J Med, Vol. 73, No. 1. (January 2006), pp. 65-71. by A. N. Makaryus, S. I. McFarlane posted by 1 person scottd2104
	Pediatric anaphylaxis. [My Copy] Pediatr Emerg Care, Vol. 23, No. 1. (January 2007) by R. D. Lane, R. G. Bolte posted by 1 person scottd2104
	Emergencies in allergy practice. [My Copy] J Dtsch Dermatol Ges, Vol. 5, No. 3. (March 2007), pp. 230-245. by D. Berner, J. Fischer, T. Biedermann posted by 1 person scottd2104
	Anaphylaxis during the perioperative period. [My Copy] Anesth Analg, Vol. 97, No. 5. (November 2003), pp. 1381-1395. by D. L. Hepner, M. C. Castells posted by 1 person scottd2104
	DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. [My Copy] Blood, Vol. 74, No. 6. (1 November 1989), pp. 1972-1975. by M. Cattaneo, M. Moia, P. Delle Valle, P. Castellana, P. M. Mannucci posted by 1 person scottd2104
	Uremic bleeding: pathogenesis and therapy. [My Copy] Am J Med Sci, Vol. 316, No. 2. (August 1998), pp. 94-104. by A. L. Weigert, A. I. Schafer posted by 1 person scottd2104
	Is the bleeding time predictive of bleeding prior to a percutaneous renal biopsy? [My Copy] Curr Opin Nephrol Hypertens, Vol. 8, No. 6. (November 1999), pp. 715-718. by H. Mattix, A. K. Singh posted by 1 person scottd2104
	DDAVP (desmopressin; 1-deamino-cys-8-D-arginine-vasopressin) treatment in children with haemophilia B. [My Copy] Br J Haematol, Vol. 111, No. 4. (December 2000), pp. 1260-1262. by S. Ehl, T. Severin, A. H. Sutor posted by 1 person scottd2104
	Uremic bleeding: pathophysiology and clinical risk factors. [My Copy] Thromb Res, Vol. 118, No. 3. (2006), pp. 417-422. by A. S. Sohal, A. S. Gangji, M. A. Crowther, D. Treleaven posted by 1 person scottd2104
	Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. [My Copy] Clin Pharmacol Ther, Vol. 57, No. 6. (June 1995), pp. 601-609. by D. L. Vargo, W. G. Kramer, P. K. Black, W. B. Smith, T. Serpas, D. C. Brater posted by 1 person scottd2104
	The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. [My Copy] Am J Med, Vol. 104, No. 6. (June 1998), pp. 533-538. by S. S. Gottlieb, M. Khatta, D. Wentworth, D. Roffman, M. L. Fisher, W. G. Kramer posted by 1 person scottd2104
	A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. [My Copy] Br J Urol, Vol. 81, No. 2. (February 1998), pp. 215-218. by J. M. Reynard, A. Cannon, Q. Yang, P. Abrams posted by 1 person scottd2104
	Health-related consequences of overactive bladder. [My Copy] Am J Manag Care, Vol. 8, No. 19 Suppl. (December 2002) by T. H. Wagner, T. W. Hu, J. Bentkover, et al.K. LeBlanc, W. Stewart, R. Corey, Z. Zhou, T. Hunt posted by 1 person scottd2104
	ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. [My Copy] Circulation, Vol. 104, No. 24. (11 December 2001), pp. 2996-3007. by S. A. Hunt, D. W. Baker, M. H. Chin, et al.M. P. Cinquegrani, A. M. Feldman, G. S. Francis, T. G. Ganiats, S. Goldstein, G. Gregoratos, M. L. Jessup, R. J. Noble, M. Packer, M. A. Silver, L. W. Stevenson, R. J. Gibbons, E. M. Antman, J. S. Alpert, D. P. Faxon, V. Fuster, G. Gregoratos, A. K. Jacobs, L. F. Hiratzka, R. O. Russell, S. C. Smith, , , posted by 1 person scottd2104
	Eliminating Inpatient Sliding-Scale Insulin: A reeducation project with medical house staff [My Copy] Diabetes Care, Vol. 28, No. 5. (1 May 2005), pp. 1008-1011. by David Baldwin, Griselda Villanueva, Robert Mcnutt, Sarika Bhatnagar posted by 3 people scottd2104 midastocar renocentric
	Standards of medical care in diabetes--2007. [My Copy] Diabetes Care, Vol. 30 Suppl 1 (January 2007) by posted by 5 people foodstamps_0809 mallinga guhjy scottd2104 mmolina
	H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review [My Copy] Allergy, Vol. 62, No. 8. (August 2007), pp. 830-837. by Sheikh, A., Ten Broek, et al. V., Brown, S. G. A., Simons, F. E. R. posted by 1 person scottd2104
	Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. [My Copy] The New England journal of medicine, Vol. 347, No. 20. (14 November 2002), pp. 1557-1565. by Paul M. Ridker, Nader Rifai, Lynda Rose, Julie E. Buring, Nancy R. Cook posted by 1 person nm61591
	C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. [My Copy] The New England journal of medicine, Vol. 342, No. 12. (23 March 2000), pp. 836-843. by P. M. Ridker, C. H. Hennekens, J. E. Buring, N. Rifai posted by 1 person nm61591
	Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. [My Copy] The New England journal of medicine, Vol. 336, No. 14. (3 April 1997), pp. 973-979. by P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, C. H. Hennekens posted by 1 person nm61591
	Inflammatory markers and risk of developing type 2 diabetes in women. [My Copy] Diabetes, Vol. 53, No. 3. (March 2004), pp. 693-700. by Frank B. Hu, James B. Meigs, Tricia Y. Li, Nader Rifai, JoAnn E. Manson posted by 1 person nm61591
	Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. [My Copy] Diabetes, Vol. 51, No. 4. (April 2002), pp. 1131-1137. by Andreas Festa, Ralph D'Agostino, Russell P. Tracy, Steven M. Haffner, Insulin Resistance Atherosclerosis Study posted by 1 person nm61591
	The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. [My Copy] Diabetes, Vol. 50, No. 10. (October 2001), pp. 2384-2389. by J. I. Barzilay, L. Abraham, S. R. Heckbert, et al.M. Cushman, L. H. Kuller, H. E. Resnick, R. P. Tracy posted by 1 person nm61591
	Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. [My Copy] Journal of molecular medicine (Berlin, Germany), Vol. 81, No. 8. (August 2003), pp. 455-470. by Marc Y. Donath, Joachim Størling, Kathrin Maedler, Thomas Mandrup-Poulsen posted by 1 person nm61591
	Is type II diabetes mellitus a disease of the innate immune system? [My Copy] Diabetologia, Vol. 41, No. 10. (October 1998), pp. 1241-1248. by J. C. Pickup, M. A. Crook posted by 1 person nm61591
	Inflammation as a cardiovascular risk factor. [My Copy] Circulation, Vol. 109, No. 21 Suppl 1. (1 June 2004) by James T. Willerson, Paul M. Ridker posted by 1 person nm61591
	Insulin as an anti-inflammatory and antiatherogenic modulator. [My Copy] Journal of the American College of Cardiology, Vol. 53, No. 5 Suppl. (3 February 2009) by Paresh Dandona, Ajay Chaudhuri, Husam Ghanim, Priya Mohanty posted by 1 person nm61591
	Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. [My Copy] The American journal of cardiology, Vol. 99, No. 4A. (19 February 2007) by Paresh Dandona, Ajay Chaudhuri, Husam Ghanim, Priya Mohanty posted by 1 person nm61591
	Correlation between cardiovascular disease and diabetes mellitus: current concepts. [My Copy] The American journal of medicine, Vol. 116 Suppl 5A (8 March 2004) by Richard W. Nesto posted by 1 person nm61591
	Independent anti-inflammatory effect of insulin in newly diagnosed type 2 diabetes. [My Copy] Diabetes/metabolism research and reviews, Vol. 25, No. 5. (July 2009), pp. 435-441. by Xiao-Ming M. Mao, Hao Liu, Xiao-Jun J. Tao, Guo-Ping P. Yin, Qian Li, Shu-Kui K. Wang posted by 1 person nm61591
	The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. [My Copy] Archives of internal medicine, Vol. 157, No. 21. (24 November 1997), pp. 2413-2446. posted by 1 person nm61591
	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. [My Copy] BMJ (Clinical research ed.), Vol. 321, No. 7258. (12 August 2000), pp. 412-419. by A. I. Adler, I. M. Stratton, H. A. Neil, et al.J. S. Yudkin, D. R. Matthews, C. A. Cull, A. D. Wright, R. C. Turner, R. R. Holman posted by 1 person nm61591
	C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. [My Copy] Diabetes, Vol. 51, No. 5. (May 2002), pp. 1596-1600. by Dilys J. Freeman, John Norrie, Muriel J. Caslake, et al.Allan Gaw, Ian Ford, Gordon D. Lowe, Denis St S. O'Reilly, Chris J. Packard, Naveed Sattar, West of Scotland Coronary Prevention Study posted by 2 people nm61591 booker
	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. [My Copy] Journal of the American College of Cardiology, Vol. 53, No. 3. (20 January 2009), pp. 298-304. by Jay S. Skyler, Richard Bergenstal, Robert O. Bonow, et al.John Buse, Prakash Deedwania, Edwin A. Gale, Barbara V. Howard, M. Sue Kirkman, Mikhail Kosiborod, Peter Reaven, Robert S. Sherwin, American Diabetes Association, American College of Cardiology Foundation, American Heart Association posted by 4 people ggrassi booker nm61591 guhjy
	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. [My Copy] Circulation (17 December 2008) by Jay S S. Skyler, Richard Bergenstal, Robert O O. Bonow, et al.John Buse, Prakash Deedwania, Edwin A M A. Gale, Barbara V V. Howard, M Sue S. Kirkman, Mikhail Kosiborod, Peter Reaven, Robert S S. Sherwin posted by 2 people booker nm61591
	Glucose control and vascular complications in veterans with type 2 diabetes. [My Copy] The New England journal of medicine, Vol. 360, No. 2. (8 January 2009), pp. 129-139. by William Duckworth, Carlos Abraira, Thomas Moritz, et al.Domenic Reda, Nicholas Emanuele, Peter D. Reaven, Franklin J. Zieve, Jennifer Marks, Stephen N. Davis, Rodney Hayward, Stuart R. Warren, Steven Goldman, Madeline McCarren, Mary Ellen E. Vitek, William G. Henderson, Grant D. Huang, VADT Investigators posted by 9 people booker familydoc guhjy omalbam hmoffet Anesthesia and Acute Pain richardh nm61591 djmonstermo
	Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. [My Copy] Lancet, Vol. 366, No. 9500. (26 November 2005), pp. 1849-1861. by A. Keech, R. J. Simes, P. Barter, et al.J. Best, R. Scott, M. R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou, P. Drury, Y. A. Kesäniemi, D. Sullivan, D. Hunt, P. Colman, M. d'Emden, M. Whiting, C. Ehnholm, M. Laakso, FIELD study investigators posted by 2 people guhjy nm61591
	Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. [My Copy] Circulation, Vol. 102, No. 1. (4 July 2000), pp. 21-27. posted by 1 person nm61591
	Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. [My Copy] The New England journal of medicine, Vol. 341, No. 6. (5 August 1999), pp. 410-418. by H. B. Rubins, S. J. Robins, D. Collins, et al.C. L. Fye, J. W. Anderson, M. B. Elam, F. H. Faas, E. Linares, E. J. Schaefer, G. Schectman, T. J. Wilt, J. Wittes posted by 1 person nm61591
	Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. [My Copy] Lancet, Vol. 357, No. 9260. (24 March 2001), pp. 905-910. posted by 1 person nm61591
	Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. [My Copy] The New England journal of medicine, Vol. 317, No. 20. (12 November 1987), pp. 1237-1245. by M. H. Frick, O. Elo, K. Haapa, et al.O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen posted by 1 person nm61591
	Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. [My Copy] Archives of internal medicine, Vol. 159, No. 22. (7 1999), pp. 2661-2667. by S. M. Haffner, C. M. Alexander, T. J. Cook, et al.S. J. Boccuzzi, T. A. Musliner, T. R. Pedersen, J. Kjekshus, K. Pyörälä posted by 1 person nm61591
	Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. [My Copy] Lancet, Vol. 366, No. 9493. (8 October 2005), pp. 1267-1278. by C. Baigent, A. Keech, P. M. Kearney, et al.L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, R. Simes, Cholesterol Treatment Trialists' (CTT) Collaborators posted by 2 people ggrassi nm61591
	Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. [My Copy] Annals of internal medicine, Vol. 140, No. 8. (20 April 2004), pp. 650-658. by S. Vijan, R. A. Hayward, posted by 1 person nm61591
	Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. [My Copy] Lancet, Vol. 364, No. 9435. (7 2004), pp. 685-696. by H. M. Colhoun, D. J. Betteridge, P. N. Durrington, et al.G. A. Hitman, H. A. Neil, S. J. Livingstone, M. J. Thomason, M. I. Mackness, V. Charlton-Menys, J. H. Fuller, posted by 1 person nm61591
	Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). [My Copy] Diabetes care, Vol. 28, No. 5. (May 2005), pp. 1151-1157. by P. S. Sever, N. R. Poulter, B. Dahlöf, et al.H. Wedel, R. Collins, G. Beevers, M. Caulfield, S. E. Kjeldsen, A. Kristinsson, G. T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren posted by 1 person nm61591
	Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. [My Copy] JAMA : the journal of the American Medical Association, Vol. 279, No. 20. (27 May 1998), pp. 1615-1622. by J. R. Downs, M. Clearfield, S. Weis, et al.E. Whitney, D. R. Shapiro, P. A. Beere, A. Langendorfer, E. A. Stein, W. Kruyer, A. M. Gotto posted by 1 person nm61591
	Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). [My Copy] Circulation, Vol. 97, No. 15. (21 April 1998), pp. 1440-1445. posted by 1 person nm61591
	Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. [My Copy] Lancet, Vol. 360, No. 9346. (23 November 2002), pp. 1623-1630. by J. Shepherd, G. J. Blauw, M. B. Murphy, et al.E. L. Bollen, B. M. Buckley, S. M. Cobbe, I. Ford, A. Gaw, M. Hyland, J. W. Jukema, A. M. Kamper, P. W. Macfarlane, A. E. Meinders, J. Norrie, C. J. Packard, I. J. Perry, D. J. Stott, B. J. Sweeney, C. Twomey, R. G. Westendorp, posted by 1 person nm61591
	Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. [My Copy] JAMA : the journal of the American Medical Association, Vol. 287, No. 24. (26 June 2002), pp. 3215-3222. by P. W. Serruys, P. de Feyter, C. Macaya, et al.N. Kokott, J. Puel, M. Vrolix, A. Branzi, M. C. Bertolami, G. Jackson, B. Strauss, B. Meier, posted by 1 person nm61591
	Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. [My Copy] Diabetes, Vol. 48, No. 6. (June 1999), pp. 1289-1294. by B. J. Hoogwerf, A. Waness, M. Cressman, et al.J. Canner, L. Campeau, M. Domanski, N. Geller, A. Herd, A. Hickey, D. B. Hunninghake, G. L. Knatterud, C. White posted by 1 person nm61591
	Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. [My Copy] The New England journal of medicine, Vol. 339, No. 19. (5 November 1998), pp. 1349-1357. posted by 1 person nm61591
	Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. [My Copy] Circulation, Vol. 98, No. 23. (8 December 1998), pp. 2513-2519. by R. B. Goldberg, M. J. Mellies, F. M. Sacks, et al.L. A. Moyé, B. V. Howard, W. J. Howard, B. R. Davis, T. G. Cole, M. A. Pfeffer, E. Braunwald posted by 1 person nm61591
	Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [My Copy] Lancet, Vol. 344, No. 8934. (19 November 1994), pp. 1383-1389. posted by 2 people aleeva nm61591
	The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. [My Copy] JAMA : the journal of the American Medical Association, Vol. 251, No. 3. (20 January 1984), pp. 351-364. posted by 1 person nm61591
	Diabetes and coronary risk equivalency: what does it mean? [My Copy] Diabetes care, Vol. 29, No. 2. (February 2006), pp. 457-460. by S. M. Grundy posted by 1 person nm61591
	Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. [My Copy] Archives of internal medicine, Vol. 157, No. 2. (27 January 1997), pp. 181-188. by C. Abraira, J. Colwell, F. Nuttall, et al.C. T. Sawin, W. Henderson, J. P. Comstock, N. V. Emanuele, S. R. Levin, I. Pacold, H. S. Lee posted by 1 person nm61591
	Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. [My Copy] Annals of internal medicine, Vol. 124, No. 1 Pt 2. (1 January 1996), pp. 104-109. by S. Genuth posted by 1 person nm61591
	Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. [My Copy] Journal of the American College of Cardiology, Vol. 26, No. 1. (July 1995), pp. 57-65. by K. Malmberg, L. Rydén, S. Efendic, et al.J. Herlitz, P. Nicol, A. Waldenström, H. Wedel, L. Welin posted by 2 people booker nm61591
	Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. [My Copy] Annals of internal medicine, Vol. 141, No. 6. (21 September 2004), pp. 413-420. by K. T. Khaw, N. Wareham, S. Bingham, R. Luben, A. Welch, N. Day posted by 2 people booker nm61591
	The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. [My Copy] Endocrine reviews, Vol. 19, No. 5. (October 1998), pp. 583-592. by S. M. Haffner posted by 5 people HEIRS - Environmental Illness Research HEIRS Diabetes, Insulin Resistance and Metabolic Syndrome Research HEIRS Cardiology HEIRS nm61591
	Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. [My Copy] Diabetes care, Vol. 22, No. 1. (January 1999), pp. 45-49. by J. V. Bjørnholt, G. Erikssen, E. Aaser, et al.L. Sandvik, S. Nitter-Hauge, J. Jervell, J. Erikssen, E. Thaulow posted by 1 person nm61591
	High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. [My Copy] Diabetes care, Vol. 21, No. 3. (March 1998), pp. 360-367. by B. Balkau, M. Shipley, R. J. Jarrett, et al.K. Pyörälä, M. Pyörälä, A. Forhan, E. Eschwège posted by 1 person nm61591
	Dysglycaemia and risk of cardiovascular disease. [My Copy] Lancet, Vol. 347, No. 9006. (6 April 1996), pp. 949-950. by H. C. Gerstein, S. Yusuf posted by 1 person nm61591
	Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. [My Copy] Journal of the American College of Cardiology, Vol. 33, No. 3. (March 1999), pp. 612-619. by H. C. Gerstein, P. Pais, J. Pogue, S. Yusuf posted by 1 person nm61591
	The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. [My Copy] Diabetes care, Vol. 22, No. 2. (February 1999), pp. 233-240. by M. Coutinho, H. C. Gerstein, Y. Wang, S. Yusuf posted by 2 people booker nm61591
	Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. [My Copy] Annals of internal medicine, Vol. 141, No. 6. (21 September 2004), pp. 421-431. by E. Selvin, S. Marinopoulos, G. Berkenblit, et al.T. Rami, F. L. Brancati, N. R. Powe, S. H. Golden posted by 1 person nm61591
	Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. [My Copy] Diabetes, Vol. 46, No. 8. (August 1997), pp. 1354-1359. by S. Lehto, T. Rönnemaa, S. M. Haffner, K. Pyörälä, V. Kallio, M. Laakso posted by 1 person nm61591
	Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. [My Copy] BMJ (Clinical research ed.), Vol. 321, No. 7258. (12 August 2000), pp. 405-412. by I. M. Stratton, A. I. Adler, H. A. Neil, et al.D. R. Matthews, S. E. Manley, C. A. Cull, D. Hadden, R. C. Turner, R. R. Holman posted by 2 people booker nm61591
	Development of macrovascular diseases in NIDDM patients in northern Taiwan. A 4-yr follow-up study. [My Copy] Diabetes care, Vol. 16, No. 1. (January 1993), pp. 137-143. by C. C. Fu, C. J. Chang, C. H. Tseng, et al.M. S. Chen, C. S. Kao, T. J. Wu, H. P. Wu, L. M. Chuang, C. J. Chen, T. Y. Tai posted by 1 person nm61591
	Macrovascular disease and hyperglycaemia: 10-year survival analysis in Type 2 diabetes mellitus: the Belfast Diet Study. [My Copy] Diabetic medicine : a journal of the British Diabetic Association, Vol. 14, No. 8. (August 1997), pp. 663-672. by D. R. Hadden, C. C. Patterson, A. B. Atkinson, et al.L. Kennedy, P. M. Bell, D. R. McCance, J. A. Weaver posted by 1 person nm61591
	Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. [My Copy] Diabetes care, Vol. 21, No. 7. (July 1998), pp. 1167-1172. by M. Wei, S. P. Gaskill, S. M. Haffner, M. P. Stern posted by 1 person nm61591
	The U.K. Prospective Diabetes Study. A review. [My Copy] Diabetes care, Vol. 21 Suppl 3 (December 1998) by R. C. Turner posted by 1 person nm61591
	Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. [My Copy] The American journal of cardiology, Vol. 80, No. 2. (15 July 1997), pp. 164-169. by S. Agewall, J. Wikstrand, S. Ljungman, B. Fagerberg posted by 1 person nm61591
	Albuminuria and poor glycemic control predict mortality in NIDDM. [My Copy] Diabetes, Vol. 44, No. 11. (November 1995), pp. 1303-1309. by M. A. Gall, K. Borch-Johnsen, P. Hougaard, F. S. Nielsen, H. H. Parving posted by 1 person nm61591
	Long-term glycemic control relates to mortality in type II diabetes. [My Copy] Diabetes care, Vol. 18, No. 12. (December 1995), pp. 1534-1543. by D. K. Andersson, K. Svärdsudd posted by 1 person nm61591
	NIDDM and its metabolic control predict coronary heart disease in elderly subjects. [My Copy] Diabetes, Vol. 43, No. 8. (August 1994), pp. 960-967. by J. Kuusisto, L. Mykkänen, K. Pyörälä, M. Laakso posted by 2 people takumi nm61591
	The association of glycemia and cause-specific mortality in a diabetic population. [My Copy] Archives of internal medicine, Vol. 154, No. 21. (14 November 1994), pp. 2473-2479. by S. E. Moss, R. Klein, B. E. Klein, S. M. Meuer posted by 1 person nm61591
	Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. [My Copy] Circulation, Vol. 102, No. 9. (29 August 2000), pp. 1014-1019. by K. Malmberg, S. Yusuf, H. C. Gerstein, et al.J. Brown, F. Zhao, D. Hunt, L. Piegas, J. Calvin, M. Keltai, A. Budaj posted by 1 person nm61591
	Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. [My Copy] Journal of the American College of Cardiology, Vol. 30, No. 1. (July 1997), pp. 171-179. by K. H. Mak, D. J. Moliterno, C. B. Granger, et al.D. P. Miller, H. D. White, R. G. Wilcox, R. M. Califf, E. J. Topol posted by 1 person nm61591
	Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. [My Copy] American heart journal, Vol. 133, No. 3. (March 1997), pp. 290-296. by S. Behar, V. Boyko, H. Reicher-Reiss, U. Goldbourt posted by 1 person nm61591
	Recent trends in cardiovascular complications among men and women with and without diabetes. [My Copy] Diabetes care, Vol. 29, No. 1. (January 2006), pp. 32-37. by G. L. Booth, M. K. Kapral, K. Fung, J. V. Tu posted by 1 person nm61591
	Trends in cardiovascular complications of diabetes. [My Copy] JAMA : the journal of the American Medical Association, Vol. 292, No. 20. (24 November 2004), pp. 2495-2499. by C. S. Fox, S. Coady, P. D. Sorlie, et al.D. Levy, J. B. Meigs, R. B. D'Agostino, P. W. Wilson, P. J. Savage posted by 1 person nm61591
	Diabetes and decline in heart disease mortality in US adults. [My Copy] JAMA : the journal of the American Medical Association, Vol. 281, No. 14. (14 April 1999), pp. 1291-1297. by K. Gu, C. C. Cowie, M. I. Harris posted by 1 person nm61591
	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. [My Copy] Lancet, Vol. 355, No. 9200. (22 January 2000), pp. 253-259. posted by 2 people guhjy nm61591